Valuation: Fate Therapeutics, Inc.

Market Cap 326M 282M 264M 242M 455M 31.06B 462M 3.09B 1.21B 15.57B 1.23B 1.2B 51.47B P/E 2026 *
-2.59x
P/E 2027 * -2.72x
Enterprise Value 326M 282M 264M 242M 455M 31.06B 462M 3.09B 1.21B 15.57B 1.23B 1.2B 51.47B EV / Sales 2026 *
62.2x
EV / Sales 2027 * 62.3x
Free-Float
98.91%
Yield 2026 *
-
Yield 2027 * -
1 day+12.45%
1 week+14.29%
Current month+14.29%
1 month-4.44%
3 months+17.15%
6 months+145.61%
Current year+184.96%
1 week 2.37
Extreme 2.37
2.88
1 month 2.25
Extreme 2.25
3.23
Current year 0.97
Extreme 0.97
3.23
1 year 0.91
Extreme 0.910001
3.23
3 years 0.66
Extreme 0.66105
8.83
5 years 0.66
Extreme 0.66105
97.43
10 years 0.66
Extreme 0.66105
121.16
Manager TitleAgeSince
Chief Executive Officer 49 01/01/2025
Director of Finance/CFO 47 20/10/2025
Chief Operating Officer - 01/07/2021
Director TitleAgeSince
Chairman 78 01/12/2011
Director/Board Member 70 17/03/2014
Director/Board Member 47 31/07/2018
Date Insider Type Main position Quantity % Market Cap.
4/8/26 Sell

Chief Executive Officer

-43,947 0.0377%
4/8/26 Sell

Compliance Officer

-38,800 0.0333%
12/6/26
Redmile Group LLC
FreeCompany 87,900 0.0754%
Change 5-day change 1-year change 3-year change Capi.($)
+12.45%+14.29%+203.89%-20.68% 326M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +4.70%+11.94%+68.98%+184.79% 26.39B
Weighted average by Cap. +4.37%+13.10%+50.88%+168.24%

Financials

2026 *2027 *
Net sales 5.25M 4.54M 4.24M 3.89M 7.31M 499M 7.43M 49.73M 19.52M 250M 19.7M 19.27M 827M 5.24M 4.53M 4.23M 3.88M 7.3M 498M 7.41M 49.63M 19.48M 250M 19.66M 19.23M 826M
Net income -133M -115M -107M -98.3M -185M -12.62B -188M -1.26B -493M -6.33B -498M -487M -20.92B -148M -128M -120M -110M -206M -14.08B -209M -1.4B -550M -7.06B -556M -543M -23.33B
Net Debt - -
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
07/08/26 USD 2.800 +12.45% 4,015,589
06/08/26 USD 2.490 -4.23% 2,227,408
05/08/26 USD 2.600 +1.17% 3,387,489
04/08/26 USD 2.570 +2.80% 6,440,801
03/08/26 USD 2.500 +2.04% 1,252,982
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2.800USD
Average target price
5.411USD
Spread / Average Target
+93.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FATE Stock